The cannabis sector in Brazil is receiving a helping hand from Canada, as both countries are working together for the good of the industry. Canada is planning to help with the production of the first Brazilian cannabis drug, sending raw materials to the Latin American country. It’s expected that the first wave of cannabis products will be available in pharmacies, in the coming weeks.
Brains Bioceutical Corporation, a company based in Vancouver, Canada, will supply the raw material necessary to produce the first Brazilian cannabis drug approved by the National Health Surveillance Agency (ANVISA). The pharmacist authorized to market the phytopharmaceutical drug is Prati-Donaduzzi, from Paraná, which will import the extract, since cannabis cultivation has not been authorized in the Latin American countries.
The product will be an oral cannabidiol solution (CBD) in a 30 ml bottle with a concentration of 200 mg/ml and <0.2% THC. The company did not disclose the value for which the product will be marketed to pharmacies and distributors.
However, according to a medical source in Paraná, the oil will be sold to pharmacies for about $325 (€300). “I received a visit from a commercial representative from Prati-Donaduzzi. She knew I prescribed cannabis and came to visit me to show me their product,” said the same health professional.
If you want to know more about cannabis, how Canada has decided to partner with Brazil in order to expand the cannabis sector and to find out the latest cannabis news, download the Hemp.im mobile application.
CBD not being considered as a medicine in order to introduce it earlier to the market
The authorized CBD oil is not considered a medicine by the National Health Surveillance Agency (ANVISA), but a separate category, that of “Cannabis-based products”. It was the solution the agency found for the plant derivatives to enter the market faster, without going through clinical tests, which take years. For this reason, the price of the product will not need the approval of the Brazilian Drug Market Regulation Chamber, being the responsibility of the pharmaceutical company itself.
According to Prati-Donaduzzi, the oil will be produced at the pharmacy’s plant in the city of Toledo, in the interior of Paraná. The product is expected to be available in pharmacies around the country before Mother’s Day in Brazil, May 10th.
Brains Bioceutical presents itself as the global leader in the production of Active Pharmaceutical Ingredients (API) based on pharmaceutical, welfare and veterinary cannabidiol. The company will export the European GMP API from the UK to the Brazilian pharmaceutical company to formulate the product that will be sold in pharmacies and distributors.
Working together in a partnership that aims to boost the cannabis sector
In a statement, the company announced the partnership as “a historic achievement to bring the first registered medical cannabis product from Brazil.”
“Our partners in Brazil are global leaders in pharmaceutical production and clinical trials. I am very proud of this historic moment, when we combine our forces to create the first registered product under the new regime. The standard we set for Brains’ team of world-renowned scientists and executives continues to reach milestones with a tireless quest for historic innovations in the CBD sector. We look forward to capitalizing on the resulting market opportunities. We now register the CBD product at the epicenter of the European continent in the UK. Then we supply the CBD material to our South American partner to obtain the first registered cannabis product under the new Anvisa regulations in Brazil,” concluded Rick Brar, President and CEO of Brains Bioceutical.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Canna Reporter, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.